286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
First, we delve into the fallout over the FTC's move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves unanswered question. We also ...
14 Dec 202334min
285: CRISPR history, biotech struggles, & a big week for deals
With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atla...
7 Dec 202336min
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoni...
30 Nov 202328min
283: A CRISPR milestone, algorithms amok, & biotech mixology
Our colleague Casey Ross joins us to tell the bombshell story of how the nation's largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veter...
16 Nov 202330min
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
From our reporting partners at Tradeoffs: Congress banned most surprise medical bills back in 2020, with one major exception: ambulance rides. Most people agree that patients should be shielded from t...
13 Nov 202329min
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curi...
9 Nov 202337min
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future ...
2 Nov 202332min
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week's big oncology conference in Europe. We also discuss the latest news in t...
26 Okt 202329min
